Literature DB >> 7911827

PET studies of the presynaptic and postsynaptic dopaminergic system in Tourette's syndrome.

N Turjanski1, G V Sawle, E D Playford, R Weeks, A A Lammerstma, A J Lees, D J Brooks.   

Abstract

Dysfunction of the dopaminergic pathway has been postulated to underlie the symptomatology of Tourette's syndrome. Presynaptic functional integrity of dopaminergic terminals was assessed with 18F-dopa PET in 10 patients with Tourette's syndrome, three of whom were drug free and seven of whom were on neuroleptic treatment. Dopamine D2 receptor site density was measured with 11C-raclopride PET in a further group of five drug free patients with Tourette's syndrome. Mean caudate and putamen 18F-dopa influx constants were similar in patients with Tourette's syndrome and controls, and there was no difference in striatal 18F-dopa uptake between the treated and untreated Tourette's syndrome groups. Mean caudate and putamen 11C-raclopride binding potentials in patients with Tourette's syndrome were also similar to control values. The findings suggest that striatal metabolism of exogenous levodopa and the density of striatal D2 receptors are both normal in patients with Tourette's syndrome and that Tourette's syndrome does not arise from a primary dysfunction of dopaminergic terminals.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7911827      PMCID: PMC1072970          DOI: 10.1136/jnnp.57.6.688

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  22 in total

Review 1.  Positron emission tomography evaluation of dopamine D-2 receptors in adults with Tourette syndrome.

Authors:  H S Singer; D F Wong; J E Brown; J Brandt; L Krafft; E Shaya; R F Dannals; H N Wagner
Journal:  Adv Neurol       Date:  1992

Review 2.  Tourette's syndrome: current concepts.

Authors:  R Kurlan
Journal:  Neurology       Date:  1989-12       Impact factor: 9.910

3.  Cocaine and Tourette's syndrome.

Authors:  S A Factor; J R Sanchez-Ramos; W J Weiner
Journal:  Ann Neurol       Date:  1988-04       Impact factor: 10.422

4.  Cocaine and Tourette's syndrome.

Authors:  M M Mesulam
Journal:  N Engl J Med       Date:  1986-08-07       Impact factor: 91.245

5.  Gilles de la tourette syndrome: studies with the fluorine-18-labeled fluorodeoxyglucose positron emission tomographic method.

Authors:  T N Chase; N L Foster; P Fedio; R Brooks; L Mansi; R Kessler; G Di Chiro
Journal:  Ann Neurol       Date:  1984       Impact factor: 10.422

6.  Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET.

Authors:  L Farde; H Hall; E Ehrin; G Sedvall
Journal:  Science       Date:  1986-01-17       Impact factor: 47.728

7.  Biogenic amine metabolism in Tourette syndrome.

Authors:  I J Butler; S H Koslow; W E Seifert; R M Caprioli; H S Singer
Journal:  Ann Neurol       Date:  1979-07       Impact factor: 10.422

Review 8.  [Gilles de la Tourette's syndrome. Current status of tic disease].

Authors:  M Dugas
Journal:  Presse Med       Date:  1985-03-09       Impact factor: 1.228

9.  Selective inhibition of mesolimbic dopamine release following chronic administration of clozapine: involvement of alpha 1-noradrenergic receptors demonstrated by in vivo voltammetry.

Authors:  R F Lane; C D Blaha; J M Rivet
Journal:  Brain Res       Date:  1988-09-20       Impact factor: 3.252

10.  Gilles de la Tourette's syndrome. Familial occurrence and precipitation by methylphenidate therapy.

Authors:  M A Pollack; N L Cohen; A J Friedhoff
Journal:  Arch Neurol       Date:  1977-10
View more
  12 in total

Review 1.  Neuropsychiatry of the basal ganglia.

Authors:  H A Ring; J Serra-Mestres
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-01       Impact factor: 10.154

Review 2.  The biochemistry of Tourette's syndrome.

Authors:  P R Chokka; G B Baker; R A Bornstein; C M de Groot
Journal:  Metab Brain Dis       Date:  1995-06       Impact factor: 3.584

3.  Similar striatal D2/D3 dopamine receptor availability in adults with Tourette syndrome compared with healthy controls: A [(11) C]-(+)-PHNO and [(11) C]raclopride positron emission tomography imaging study.

Authors:  Elia Abi-Jaoude; Barbara Segura; Ignacio Obeso; Sang Soo Cho; Sylvain Houle; Anthony E Lang; Pablo Rusjan; Paul Sandor; Antonio P Strafella
Journal:  Hum Brain Mapp       Date:  2015-03-18       Impact factor: 5.038

Review 4.  Functional neuroimaging in child psychiatry.

Authors:  M Ernst; J M Rumsey
Journal:  Curr Psychiatry Rep       Date:  2000-04       Impact factor: 5.285

Review 5.  Gilles de la Tourette's syndrome and its impact in the UK.

Authors:  J S Stern; S Burza; M M Robertson
Journal:  Postgrad Med J       Date:  2005-01       Impact factor: 2.401

Review 6.  The dopamine hypothesis of schizophrenia: version III--the final common pathway.

Authors:  Oliver D Howes; Shitij Kapur
Journal:  Schizophr Bull       Date:  2009-03-26       Impact factor: 9.306

7.  18F-Branched-Chain Amino Acids: Structure-Activity Relationships and PET Imaging Potential.

Authors:  Matthew B Nodwell; Hua Yang; Helen Merkens; Noeen Malik; Milena Čolović; Rainer E Martin; François Bénard; Paul Schaffer; Robert Britton
Journal:  J Nucl Med       Date:  2019-01-25       Impact factor: 10.057

8.  Widespread abnormality of the γ-aminobutyric acid-ergic system in Tourette syndrome.

Authors:  Alicja Lerner; Anto Bagic; Janine M Simmons; Zoltan Mari; Omer Bonne; Ben Xu; Diane Kazuba; Peter Herscovitch; Richard E Carson; Dennis L Murphy; Wayne C Drevets; Mark Hallett
Journal:  Brain       Date:  2012-05-10       Impact factor: 13.501

Review 9.  Molecular imaging studies of the striatal dopaminergic system in psychosis and predictions for the prodromal phase of psychosis.

Authors:  Oliver D Howes; Andrew J Montgomery; Marie-Claude Asselin; Robin M Murray; Paul M Grasby; Philip K McGuire
Journal:  Br J Psychiatry Suppl       Date:  2007-12

Review 10.  The histaminergic network in the brain: basic organization and role in disease.

Authors:  Pertti Panula; Saara Nuutinen
Journal:  Nat Rev Neurosci       Date:  2013-07       Impact factor: 34.870

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.